Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AKT-1 antisense oligonucleotide WGI-0301

A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, with potential antineoplastic activity. Upon administration of AS ODN WGI-0301, archexin binds to Akt-1 mRNA, inhibiting translation of the transcript. Suppression of Akt-1 expression may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt-1 is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Akt-1 antisense ODN WGI-0301
Akt-1 AS ODN WGI-0301
Code name:WGI 0301
WGI-0301
WGI0301
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search